BioMarin Pharma (BMRN) Misses Q4 EPS Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BioMarin (BMRN) Reiterates Profitability in 2017 - Piper Jaffray
February 26, 2016 9:46 AM ESTPiper Jaffray analyst, Joshua Schimmer, sees numerous catalysts for BioMarin (NASDAQ: BMRN) as the company marches toward profitability. No change to Overweight rating but the PT is revised down to $107.
BMRN has spent years with aggressive opex and burning cash on a promising pipeline. But much of that pipeline is now close to graduating towards commercial products and it's time for the company to move towards generating cash flows for investors while also finding new programs to replace... More
